Mather Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mather Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$123K	Sell	776 -160	-17%	-$21.6K	﹤0.01%	892
2026 Q1	$120K	Buy	+936	New	+$117K	﹤0.01%	852
2025 Q4	–	Sell	-46	Closed	-$4.61K	–	1664
2025 Q3	$4.61K	Buy	+46	New	+$4.14K	﹤0.01%	1407
2025 Q2	–	Sell	-48	Closed	-$3.89K	–	1743
2025 Q1	$3.89K	Hold	48	–	–	﹤0.01%	1449
2024 Q4	$4.32K	Hold	48	–	–	﹤0.01%	1402
2024 Q3	$4.74K	Sell	48 -827	-95%	-$81.3K	﹤0.01%	1308
2024 Q2	$83K	Buy	875 +827	+1,723%	+$74.1K	﹤0.01%	859
2024 Q1	$4.29K	Buy	+48	New	+$4.45K	﹤0.01%	1378
2014 Q2	–	Sell	-193,710	Closed	-$9.2M	–	25
2014 Q1	$9.2M	Sell	193,710 -38,562	-17%	-$1.97M	3.37%	13
2013 Q4	$10.1M	Buy	232,272 +3,801	+2%	+$157K	3.84%	11
2013 Q3	$9.84M	Sell	228,471 -2,940	-1%	-$119K	4.08%	10
2013 Q2	$8.04M	Buy	+231,411	New	+$8.13M	3.47%	12

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Mather Group's XBI Position: Q2 2026 in Review

Mather Group reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 17% in Q2 2026, selling an estimated $21.6K and leaving 776 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #892.

Mather Group first reported a position in XBI in Q2 2013 and has held it in 12 quarters since. The position peaked at $10.1M in Q4 2013. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Mather Group held 776 shares of State Street SPDR S&P Biotech ETF worth $123K as of Q2 2026.
Mather Group sold 160 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $21.6K.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #892 holding.
Mather Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 12 quarters since.
Mather Group's State Street SPDR S&P Biotech ETF position peaked at $10.1M in Q4 2013.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.